admin – page 19 – eisai china lnc.-威尼斯人888

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it will launch its first food with function claims chocola bb® rich ceramide (notification number: b60) in drugstores, pharmacies and convenience stores throughout japan on monday, october 17. the product is japan’s first drink that is a type of food with function claims containing glucosylceramide derived from rice.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today the initiation of a global phase iii clinical study (study 307, clear study) of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (lenvatinib) in respective combination regimens with the anticancer agent everolimus and the anti-pd-1 antibody pembrolizumab as a potential first-line treatment for advanced renal cell carcinoma.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced that its european regional headquarters eisai europe ltd. (location: u.k.) has received license from the european commission for anticancer agent kisplyx® ▼ (generic name: lenvatinib mesylate, “lenvatinib”) in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (vegf) targeted therapy. following the united states, europe marks the second region where lenvatinib has been licensed for the advanced renal cell carcinoma indication.

on september 3rd 2016, the peripheral neuropathy forum is successfully held by eisai china inc. in changsha, china.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that, at its recent meeting with the u.s. food and drug administration (fda), the fda confirmed there was sufficient data to support the advancement of its novel investigational oral beta-secretase cleaving enzyme (bace) inhibitor e2609 into phase iii clinical studies. e2609 was discovered by eisai and is being jointly developed by eisai and biogen inc. (headquarters: massachusetts, united states, ceo: george a. scangos, “biogen”) for early alzheimer’s disease.